Upregulation of TIM‐3 has been reported in solid tumors including non‐small cell lung cancer (NSCLC), hepatocellular carcinoma, colorectal cancer, cervical cancer, ovarian cancer, head and neck cancer, and in hematologic tumors such as acute myelogenous leukemia, breast cancer, and non‐Hodgkin lymphoma.7, 8, 9, 10, 11, 12, 13, 14, 15, 16. Here, HAVCR2 is linked to breast carcinoma.